Tango Therapeutics (TNGX) Jessica Newcomb, PAO, Sells Shares

What Happened

• Jessica Newcomb, Principal Accounting Officer of Tango Therapeutics (TNGX), sold a total of 8,200 shares in open-market transactions on September 22, 2026, generating proceeds of $198,612. The sales were: 700 shares at $22.80 ($15,962), 5,100 shares at $23.97 ($122,238), and 2,400 shares at $25.17 ($60,412). These disposals were effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: September 22, 2026; Form 4 filed September 24, 2026 (timely within standard 2‑business‑day window).
• Sales detail and reported values:
  • 700 shares @ $22.80 (proceeds $15,962) — prices in this tranche ranged $22.37–$23.32 (footnote).
  • 5,100 shares @ $23.97 (proceeds $122,238) — prices in this tranche ranged $23.52–$24.41 (footnote).
  • 2,400 shares @ $25.17 (proceeds $60,412) — prices in this tranche ranged $24.59–$25.56 (footnote).
• The reporting indicates the transactions were made pursuant to a 10b5-1 plan adopted June 23, 2026 (footnote).
• The filing notes that the reported beneficial ownership figure includes 43,666 unvested restricted stock units (RSUs); the full post‑transaction beneficial ownership total is shown on the Form 4 (not provided here).
• Transaction code: S = Sale.

Context

• These were open‑market sales under a Rule 10b5‑1 plan, which typically indicates pre‑arranged, routine dispositions rather than discretionary trading. Sales provide less direct evidence of management’s view of the company than purchases do; retail investors often treat purchases as a stronger bullish signal.